Overview
GLOW (BPC + TB + GHK-Cu) plus KPV. Adds gut and joint anti-inflammatory coverage. The go-to blend for IBD, Crohn’s, or colitis.
What It Does
Four-peptide blend, and angiogenesis. KPV adds MC1R/MC3R anti-inflammation for gut, joints, and skin.
Reconstitution
| Vial Size | BAC Water / Solvent | Concentration |
|---|---|---|
| 80 mg | + 5 mL | GHK-Cu 10 mg/mL |
Interactive tool
Reconstitution Calculator
Enter the vial amount and diluent volume to calculate concentration. If you already have a target amount, you can also convert it to liquid volume and syringe markings. This tool does not recommend a target amount.
Calculated concentration—Enter both values above.
Optional conversion
Enter a target amount you already have and select the syringe capacity.
Calculated draw—Enter concentration inputs and a target amount.
Mathematical reference only. The calculator does not determine an appropriate target amount. Syringe capacity only changes the maximum volume that fits.
Protocol
| Phase | Frequency | Amount | Notes |
|---|---|---|---|
| Week 1 | Daily | 1 mg | Loading. 1 mg GHK-Cu + 0.2 mg each of BPC/TB/KPV per dose. |
| Week 2 | Daily | 1.5 mg | Ramp. 1.5 mg GHK-Cu + 0.3 mg each of BPC/TB/KPV per dose. |
| Weeks 3–8 | Daily | 2 mg | Working dose. 2 mg GHK-Cu + 0.4 mg each of BPC/TB/KPV per dose. |
| Aggressive | Daily (AM + PM split) | 3–4 mg | Bump here ONLY if 2+ weeks at 2 mg with zero injection-site issues AND a specific high-demand goal. Start at 3 mg (= 0.6 benefit above 3 mg/day; cost roughly doubles. |
| Off | 4 weeks | – | Mandatory copper-accumulation washout. Do not skip, especially after an Aggressive phase. |
Cycle & Timing
8 weeks on / 4 weeks off, matches GHK-Cu copper-accumulation limits.
Timing
Daily SubQ, anytime; same as GLOW base.
Population Considerations
Unisex (GHK-Cu + BPC-157 + TB-500 + KPV), same protocol for men and women, no cycle effect. Avoid in pregnancy.
Handling & Stacking
Injection site
SubQ near target tissue. Rotate.
Storage
- Freeze-dried: -4°F.
- Reconstituted: 36–46°F, protect from light.
- Best used within about 2–4 weeks, kept cold and dark (structure-based estimate, no published data); copper oxidizes with no visible colour change, so use it sooner rather than later.
Side effects
Usually minimal.
What to expect
- Broader anti-inflammatory coverage than GLOW, preferred for IBD, Crohn’s, joint inflammation, and post-surgical recovery.
- KPV adds gut/inflammatory coverage.
- 8-week cycle, 4-week washout.
- Supply math 80mg → 2 vials (8-wk @ 2 mg × 7/wk); reconstituted shelf life ~28 days.
Pairs well with
CJC-1295 No DAC + Ipamorelin (systemic GH + local repair); Thymosin Alpha-1 (immune amplification)
Avoid
NSAIDs during a repair cycle (ibuprofen/Advil/Aleve slow healing on their own; use Tylenol for pain). High-dose vitamin C same session (copper oxidation)
Safety & Patient Education
Contraindications
- Active or suspected malignancy.
- TB-500 is angiogenic systemically; BPC-157 drives angiogenesis locally via VEGF; copper is an angiogenesis cofactor.
- KPV is the one component with no growth signal.
- Theoretical, but they can’t tell healthy tissue from a tumour you don’t know about.
- Screen age-appropriately before a long run; stop for any new lump.
- Wilson’s disease, copper dysregulation, copper allergy (GHK-Cu component) Alpha-MSH allergy (KPV is an alpha-MSH C-terminal fragment) Active bleeding or recent hemorrhagic stroke (TB-500 vascular effects) Pregnancy, lactation
Warnings
- Four-compound blend with no human RCT data on the combination.
- GHK-Cu: copper accumulation risk with extended cycling, 4–6 week off period is mandatory.
- BPC-157: FDA Category 2 in 2023; compounding restricted.
- TB-500: theoretical malignancy concern via angiogenesis; no published human trials.
- KPV: limited human data; use for gut indications is community-standard but not RCT-supported.
- BPC-157, TB-500 & KPV were all RECOMMENDED for the 503A bulks list by PCAC (8–6 each, Jul 2026; advisory, non-binding).
Drug interactions
NSAIDs: don’t blunt the blend (a myth); skip during a repair cycle, NSAIDs slow healing themselves High-dose vitamin C same session: theoretical copper redox interaction (GHK-Cu) Anticoagulants: caution with TB-500 vascular effects Other alpha-MSH agonists (Melanotan I/II): theoretical receptor overlap with KPV
Labs
Compound-specific: hsCRP (baseline + end) Serum copper and ceruloplasmin if cycles extend beyond 6 weeks Out of range? Rising serum copper = it’s accumulating → re-dose lower.
Stop criteria
New mass or unexpected tissue growth at any injection site Skin discoloration or neurological symptoms (copper toxicity) New skin pigmentation changes (KPV alpha-MSH activity) Persistent injection-site reactions beyond 7 days
Patient education
- Four-peptide blend: any single-component contraindication applies to the whole blend.
- Cycle discipline: 4–6 weeks on / 4–6 weeks off.
- Continuous use without washout risks copper accumulation.
- Inject SubQ near target tissue.
- Rotate sites to reduce GHK-Cu sting.
References
researchdosing · peptidedosages · PubMed · thepeptidereport · peptides.id
